Analysts await Valeant Pharmaceuticals International, Inc. (NASDAQ:VRX) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $2.64 EPS, up 1.89% or $0.05 from last year’s $2.59 per share.

At the moment 21 analysts are watching Valeant Pharmaceuticals International, Inc. (NASDAQ:VRX), 4 rate it “Buy”, 5 “Outperform”, 10 “Underperform”, 2 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 11 analysts have a mean sales target of 2,819.03 million. For the quarter ending Jun-16, 11 analysts have a mean sales target of 3,038.65 million whilst for the year ending Dec-16, 22 analysts have a mean target of 12,410.50 million.

In terms of earnings per share, 16 analysts have a 2.63 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 16 analysts have a 3.18 EPS mean target and for the quarter ending Jun-16 there are 22 estimates of 13.24 EPS.

Total shares held by institutions as of the most recent company filings are 306,584,168 with a reported 34,398,884 bought and 14,045,316 sold. These holdings make up 66.82% of the company’s outstanding shares.

The stock decreased 0.73% or $0.51 during the last trading session, hitting $65.00. Valeant Pharmaceuticals International, Inc. (NASDAQ:VRX) has fallen 251.11% over the past 6 months and is downtrending.